Heterogeneity of Fat Depots: Biological Differences Related to Insulin Resistance

脂肪库的异质性:与胰岛素抵抗相关的生物学差异

基本信息

  • 批准号:
    8091283
  • 负责人:
  • 金额:
    $ 37.62万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-05 至 2013-03-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Insulin resistance (IR) is a major contributor to obesity-related morbidities such as diabetes and cardiovascular disease. While obesity is associated with IR, the biological basis for this association is unclear, and not all obese individuals are IR. The once-popular portal hypothesis, which states that lipolysis from VAT in particular accounts for IR, has been questioned because VAT contributes only 15% of the total systemic free fatty acid (FFA) flux. Other proposed mechanisms linking obesity to IR include inflammation, adiponectin, and ectopic fat. It is unclear whether VAT mass is more closely linked to IR than is subcutaneous adipose tissue (SAT) mass. Furthermore, evidence linking differential biological activity to IR in VAT or SAT is indirect, largely derived from studies comparing lean to obese or VAT to SAT without evaluation of IR. Thus, the purpose of this study is to investigate the biological mechanisms by which SAT and/or VAT contribute to IR. Specifically, we will explore two related hypotheses- that impaired adipocyte differentiation in SAT is related to IR, ectopic fat deposition and expansion of VAT depot, and that inflammation in VAT is associated with IR. Utilizing adipose cell size/distribution obtained by Beckman Coulter Multisizer, gene expression via quantitative PCR, in-vivo quantification of IR via a modified insulin suppression test, and imaging of intramyocellular, intraabdominal and intrahepatic fat, our specific aims are to: 1) Confirm that impairment of adipocyte differentiation in SAT is associated with IR by comparing cell size characteristics and differentiation markers in IR and IS subjects undergoing elective surgery; 2) Test the hypothesis that the same relationship will not be seen in VAT; 3) Demonstrate that VAT mass is expanded in the presence of impaired differentiation of adipocytes in SAT; 4) Demonstrate that intramuscular fat is related to both IR and impaired differentiation of adipocytes in SAT using cell size characteristics and differentiation markers; 5) Demonstrate that increased inflammation in omental fat is associated with IR independent of obesity using inflammation markers (gene and protein). Supportive data for #1,3,4 above will be derived from pioglitazone vs placebo administration to 20-23 IR individuals for 16 weeks, with hypothesized improvement in adipose cell differentiation/fat storage and associated reduction in ectopic and visceral fat with improved insulin sensitivity. PUBLIC HEALTH RELEVANCE: The prevalence of obesity continues to rise in the United States and worldwide, bringing with it associated complications of type 2 diabetes and cardiovascular disease. Insulin resistance (IR) is associated with increasing body mass index (1), and is likely to account for the majority of these complications (2). Not all obese individuals are IR, however (3,4), and there exist sufficient data to justify investigating biological characteristics of adipose tissue that might explain the development of obesity- associated IR in select individuals: 1) weight gain/loss and drugs targeting fat cells (thiazolidinediones) have the ability to alter insulin sensitivity (5,6); 2) lipodystrophy models in humans and animals are associated with altered deposition of fat and IR (7-9); 3) fat deposition in the abdominal cavity, liver, and skeletal muscle is associated with IR (10); 4) inflammatory activity in adipose tissue is higher in obese vs lean individuals (11), suggesting a possible link with IR; 5) adipose tissue produces hormones such as adiponectin (12), that may protect individuals from IR. By comparing biological properties of subcutaneous and visceral adipose tissue from obese individuals who are IR vs insulin sensitive, we will explore the hypothesis that impaired differentiation/maturation of adipose cells in subcutaneous fat, and inflammation in visceral fat contributes to IR in the setting of human obesity.
描述(由申请人提供):胰岛素抵抗(IR)是肥胖相关疾病(如糖尿病和心血管疾病)的主要原因。虽然肥胖与IR相关,但这种关联的生物学基础尚不清楚,并且并非所有肥胖个体都是IR。曾经流行的门户假说(其指出特别是来自VAT的脂解导致IR)受到质疑,因为VAT仅占全身游离脂肪酸(FFA)流量的15%。其他提出的肥胖与IR相关的机制包括炎症、脂联素和异位脂肪。目前尚不清楚VAT质量是否比皮下脂肪组织(SAT)质量与IR更密切相关。此外,将增值税或增值税中的差异生物活性与IR联系起来的证据是间接的,主要来自在没有评估IR的情况下比较瘦与肥胖或增值税与增值税的研究。因此,本研究的目的是研究SAT和/或增值税促进IR的生物学机制。具体来说,我们将探索两个相关假设--SAT中脂肪细胞分化受损与IR相关,利用Beckman Coulter Multisizer获得的脂肪细胞大小/分布,通过定量PCR进行基因表达,通过改良的胰岛素抑制试验进行IR的体内定量,以及肌细胞内、腹腔内和肝内脂肪的成像,我们的具体目标是:1)通过比较经历选择性手术的IR和IS受试者中的细胞大小特征和分化标志物,确认SAT中脂肪细胞分化的受损与IR相关; 2)测试在VAT中不会看到相同关系的假设; 3)证明在SAT中脂肪细胞分化受损的情况下VAT质量扩大; 4)使用细胞大小特征和分化标志物证明肌内脂肪与IR和SAT中脂肪细胞分化受损两者相关; 5)使用炎症标志物(基因和蛋白质)证明网膜脂肪中增加的炎症与IR相关,而与肥胖无关。上述#1,3,4的支持性数据将来自20-23名IR个体接受吡格列酮与安慰剂给药16周,假设脂肪细胞分化/脂肪储存得到改善,异位脂肪和内脏脂肪减少,胰岛素敏感性提高。公共卫生关系:肥胖症的患病率在美国和世界范围内持续上升,带来了2型糖尿病和心血管疾病的相关并发症。胰岛素抵抗(IR)与体重指数增加有关(1),并且可能是这些并发症的主要原因(2)。然而,并非所有的肥胖个体都是IR(3,4),并且存在足够的数据来证明调查脂肪组织的生物学特征是合理的,这些生物学特征可以解释在选择的个体中肥胖相关IR的发展:1)体重增加/减轻和靶向脂肪细胞的药物(噻唑烷二酮类)具有改变胰岛素敏感性的能力(5,6); 2)人和动物的脂肪代谢障碍模型与脂肪沉积和IR的改变有关(7-9); 3)腹腔、肝脏和骨骼肌中的脂肪沉积与IR有关(10); 4)肥胖者脂肪组织中的炎症活性高于瘦个体(11),表明可能与IR有关; 5)脂肪组织产生激素如脂联素(12),其可以保护个体免受IR。通过比较IR与胰岛素敏感的肥胖个体的皮下和内脏脂肪组织的生物学特性,我们将探讨皮下脂肪中脂肪细胞的分化/成熟受损和内脏脂肪中的炎症导致人肥胖背景下IR的假设。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TRACEY MCLAUGHLIN其他文献

TRACEY MCLAUGHLIN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TRACEY MCLAUGHLIN', 18)}}的其他基金

Obesity and COVID-19: Role of Adipose Tissue
肥胖和 COVID-19:脂肪组织的作用
  • 批准号:
    10302846
  • 财政年份:
    2021
  • 资助金额:
    $ 37.62万
  • 项目类别:
Obesity and COVID-19: Role of Adipose Tissue
肥胖和 COVID-19:脂肪组织的作用
  • 批准号:
    10442684
  • 财政年份:
    2021
  • 资助金额:
    $ 37.62万
  • 项目类别:
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
纵向多组学分析揭示肥胖介导的胰岛素抵抗机制
  • 批准号:
    9895799
  • 财政年份:
    2017
  • 资助金额:
    $ 37.62万
  • 项目类别:
Heterogeneity of Fat Depots: Biological Differences Related to Insulin Resistance
脂肪库的异质性:与胰岛素抵抗相关的生物学差异
  • 批准号:
    7741358
  • 财政年份:
    2009
  • 资助金额:
    $ 37.62万
  • 项目类别:
Heterogeneity of Fat Depots: Biological Differences Related to Insulin Resistance
脂肪库的异质性:与胰岛素抵抗相关的生物学差异
  • 批准号:
    7885405
  • 财政年份:
    2009
  • 资助金额:
    $ 37.62万
  • 项目类别:
WHAT ARE THE UNIQUE BENEFITS OF PIOGLITAZONE COMPARED TO WEIGHT LOSS
与减肥相比,吡格列酮有哪些独特的好处
  • 批准号:
    7605230
  • 财政年份:
    2007
  • 资助金额:
    $ 37.62万
  • 项目类别:
WHAT ARE THE UNIQUE BENEFITS OF PIOGLITAZONE COMPARED TO WEIGHT LOSS
与减肥相比,吡格列酮有哪些独特的好处
  • 批准号:
    7717883
  • 财政年份:
    2007
  • 资助金额:
    $ 37.62万
  • 项目类别:
INSULIN RESISTANCE: IT'S ROLE IN WEIGHT LOSS AND CARDIOVASCULAR RISK
胰岛素抵抗:它在减肥和心血管风险中的作用
  • 批准号:
    7605167
  • 财政年份:
    2007
  • 资助金额:
    $ 37.62万
  • 项目类别:
INSULIN RESISTANCE: IT'S ROLE IN WEIGHT LOSS AND CARDIOVASCULAR RISK
胰岛素抵抗:它在减肥和心血管风险中的作用
  • 批准号:
    7717846
  • 财政年份:
    2007
  • 资助金额:
    $ 37.62万
  • 项目类别:
INSULIN RESISTANCE: IT'S ROLE IN WEIGHT LOSS AND CARDIOVASCULAR RISK
胰岛素抵抗:它在减肥和心血管风险中的作用
  • 批准号:
    7375200
  • 财政年份:
    2005
  • 资助金额:
    $ 37.62万
  • 项目类别:

相似海外基金

Study on design method of laparoscopic surgery robot system to optimize both motion inside and outside patient's abdominal cavity
优化患者腹腔内外运动的腹腔镜手术机器人系统设计方法研究
  • 批准号:
    17K06271
  • 财政年份:
    2017
  • 资助金额:
    $ 37.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study of a miniature master-slave five fingers hand robot which can perform surgery in abdominal cavity
腹腔手术微型主从五指手机器人的研究
  • 批准号:
    16H03195
  • 财政年份:
    2016
  • 资助金额:
    $ 37.62万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Cancer stem cell for peritoneal metastasis in abdominal cavity
癌症干细胞用于腹腔腹膜转移
  • 批准号:
    24659600
  • 财政年份:
    2012
  • 资助金额:
    $ 37.62万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Critical early events in the induction of abscesses in the abdominal cavity
诱发腹腔脓肿的关键早期事件
  • 批准号:
    nhmrc : 970031
  • 财政年份:
    1997
  • 资助金额:
    $ 37.62万
  • 项目类别:
    NHMRC Project Grants
A study of simultaneous multi-organ transplantaion after hypothemic preservation using abdominal cavity cooling
腹腔低温保存后同步多器官移植的研究
  • 批准号:
    05454357
  • 财政年份:
    1993
  • 资助金额:
    $ 37.62万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了